Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lifecore BiomedicalLFCR -1.14%51 EV-to-EBITDA is 3,536.39 as of Jul. 29, 2026, which is 27485% above its 10-year median of 12.82. GuruFocus rates LFCR with a GF Score™ of 51/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 744 Drug Manufacturers companies, Lifecore Biomedical ranks worse than 99.87% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lifecore Biomedical's enterprise value is $289.98 Mil.
Lifecore Biomedical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.08 Mil. Therefore, Lifecore Biomedical's EV-to-EBITDA for today is 3,536.39.
The historical rank and industry rank for Lifecore Biomedical's EV-to-EBITDA or its related term are showing as below:
LFCR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -555.25 Med: 12.82 Max: 4138
Current: 3536.39
During the past 13 years, the highest EV-to-EBITDA of Lifecore Biomedical was 4138.00. The lowest was -555.25. And the median was 12.82.
LFCR's EV-to-EBITDA is ranked worse than 99.87% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs LFCR: 3536.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lifecore Biomedical's PE Ratio (TTM) for today is calculated as:
Lifecore Biomedical's share price for today is $4.32.
Lifecore Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lifecore Biomedical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's EV-to-EBITDA falls into.
Lifecore Biomedical's current Enterprise Value is $289.98 Mil.
Lifecore Biomedical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a EV-to-EBITDA of 3,536.39 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lifecore Biomedical. This is 27485% above median its historical median of 12.82. According to the industry distribution chart, Lifecore Biomedical ranks #743 out of 744 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is Lifecore Biomedical's EV-to-EBITDA too high?
Lifecore Biomedical's current EV-to-EBITDA of 3,536.39 is 27485% above median its 10-year median of 12.82. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Lifecore Biomedical's value of 3,536.39 is 27144.9% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #743 out of 744 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's EV-to-EBITDA compare to DERM and ADCT?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #743 out of 744 companies for EV-to-EBITDA. This places Lifecore Biomedical in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Lifecore Biomedical's value of 3,536.39 is 27144.9% above this benchmark. While the company's 10-year median is 12.82 vs. the industry median of 12.98, Lifecore Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current EV-to-EBITDA of 3,536.39 is 27144.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lifecore Biomedical. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current EV-to-EBITDA is 3,536.39, which is 27485% above median its own 10-year median of 12.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $4.32 — trading 33.1% below its estimated fair value. The current EV-to-EBITDA is 3,536.39, which is 27485% above median its 10-year median of 12.82 and 27144.9% above the Drug Manufacturers industry median of 12.98. Lifecore Biomedical's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current EV-to-EBITDA is 3,536.39 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.32 is trading 33.1% below its estimated GF Value™ of $6.46.
GuruFocus considers Lifecore Biomedical to be Possible Value Trap.
Key valuation signals for LFCR:
EV-to-EBITDA: 3,536.39 (27485% above median its 10-year median of 12.82)
GF Value™: $6.46 vs. price of $4.32 (33.1% below fair value)
Industry Position: 27144.9% above the Drug Manufacturers median (#743 of 744)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
51GF Score
Get the complete analysis for LFCR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
